WO2003060158A3 - Apoe genotype as a prognostic marker for hepatitis - Google Patents

Apoe genotype as a prognostic marker for hepatitis Download PDF

Info

Publication number
WO2003060158A3
WO2003060158A3 PCT/GB2003/000104 GB0300104W WO03060158A3 WO 2003060158 A3 WO2003060158 A3 WO 2003060158A3 GB 0300104 W GB0300104 W GB 0300104W WO 03060158 A3 WO03060158 A3 WO 03060158A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
apoe genotype
patient
prognostic marker
liver disease
Prior art date
Application number
PCT/GB2003/000104
Other languages
French (fr)
Other versions
WO2003060158A2 (en
Inventor
Ruth Itzhaki
Matthew Wozniak
William Irving
Original Assignee
Univ Manchester
Univ Nottingham
Ruth Itzhaki
Matthew Wozniak
William Irving
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester, Univ Nottingham, Ruth Itzhaki, Matthew Wozniak, William Irving filed Critical Univ Manchester
Priority to AU2003201655A priority Critical patent/AU2003201655A1/en
Publication of WO2003060158A2 publication Critical patent/WO2003060158A2/en
Publication of WO2003060158A3 publication Critical patent/WO2003060158A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for determining whether or not a patient infected with hepatitis C is likely to develop severe liver disease. The method comprises determining the ApoE genotype of the patient, where a patient expressing the ApoE4 isoform is less likely to develop severe liver disease than a patient expressing only the ApoE2 or ApoE3 isoforms.
PCT/GB2003/000104 2002-01-15 2003-01-13 Apoe genotype as a prognostic marker for hepatitis WO2003060158A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201655A AU2003201655A1 (en) 2002-01-15 2003-01-13 Apoe genotype as a prognostic marker for hepatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0200757.3 2002-01-15
GBGB0200757.3A GB0200757D0 (en) 2002-01-15 2002-01-15 Diagnostic methods

Publications (2)

Publication Number Publication Date
WO2003060158A2 WO2003060158A2 (en) 2003-07-24
WO2003060158A3 true WO2003060158A3 (en) 2004-01-08

Family

ID=9929040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000104 WO2003060158A2 (en) 2002-01-15 2003-01-13 Apoe genotype as a prognostic marker for hepatitis

Country Status (3)

Country Link
AU (1) AU2003201655A1 (en)
GB (1) GB0200757D0 (en)
WO (1) WO2003060158A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
WO2006004660A2 (en) * 2004-06-28 2006-01-12 Illumigen Biosciences, Inc. Detection of mutations in a gene associated with resistance to viral infection
US7592141B2 (en) * 2004-12-13 2009-09-22 Duke University Methods of identifying individuals at reduced risk of sepsis
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
AU2017350947B2 (en) 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031548A1 (en) * 1998-11-25 2000-06-02 Scios Inc. Prevention and treatment of amyloid-associated disorders
EP1074634A1 (en) * 1999-07-09 2001-02-07 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031548A1 (en) * 1998-11-25 2000-06-02 Scios Inc. Prevention and treatment of amyloid-associated disorders
EP1074634A1 (en) * 1999-07-09 2001-02-07 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
IMBERT-BISMUT F ET AL: "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 357, no. 9262, 7 April 2001 (2001-04-07), pages 1069 - 1075, XP004234215, ISSN: 0140-6736 *
LIN W-R ET AL.: "Apolipoprotein E and herpes virus diseases: herpes simplex keratitis", EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 7, 1999, pages 401 - 403, XP002259656 *
LIN W-R ET AL.: "Herpes simplex encephalitis: involvement of apolipoprotein E genotype", JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY, vol. 70, 2001, pages 117 - 119, XP008023633 *
NAUCK M ET AL.: "Evaluation of the Apo E Genotyping Kit on the Light-Cycler", CLINICAL CHEMISTRY, vol. 46, 2000, pages 722 - 724, XP002259654 *
PANDURO A ET AL.: "Transcriptional and posttranscriptional regulation of apolipoprotein E, A-I, and A-II gene expression in normal rat liver and during several pathophysiologic states", BIOCHEMISTRY, vol. 29, 1990, pages 8430 - 8435, XP002259655 *
UCHIDA Y ET AL.: "Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms", JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol. 14, 2000, pages 260 - 264, XP008023599 *
WENHAM P R ET AL.: "APOLOPOPROTEIN E GENOTYPING BY ONE-STAGE PCR", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 337, 11 May 1991 (1991-05-11), pages 1158 - 1159, XP000619838, ISSN: 0140-6736 *
WOZNIAK M A ET AL.: "Apolipoprotein E-epsilon4 protects against severe liver disease caused by hepatitis C virus", HEPATOLOGY, vol. 36, no. 2, 2002, pages 456 - 463, XP008023597 *

Also Published As

Publication number Publication date
AU2003201655A1 (en) 2003-07-30
AU2003201655A8 (en) 2003-07-30
WO2003060158A2 (en) 2003-07-24
GB0200757D0 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
HK1079822A1 (en) Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
WO2006131599A3 (en) Method of profiling a cell population
AU2003281416A1 (en) Level gauging system
MX2007016136A (en) Method for the diagnosis of alzheimer's disease.
WO2007035864A3 (en) Electrophoresis standards, methods and kits
AU2003251093A1 (en) Instruction cache way prediction for jump targets
WO2006072075A3 (en) Genetic markers of schizophrenia
AU2002343573A1 (en) Methods for detecting genetic haplotypes by interaction with probes
AU2003232872A1 (en) Method for determining immune system affecting compounds
WO2012079010A3 (en) Improved method and kit for determining severity and progression of periodontal disease
WO2006036943A3 (en) Determination of molecular age by detection of ink4a/arf expression
AU2002312859A1 (en) Method for determining gene expression
EP1402276A4 (en) Method of determining when electrode pads are unsuitable for use by detecting relative humidity
WO2008155891A1 (en) Novel marker for arteriosclerotic disease
WO2007023191A3 (en) Polypeptide marker for the diagnosis of bladder cancer
AU2002332462A1 (en) Weighing scale with level compensating foot assembly
WO2008014373A3 (en) Hspa1a as a marker for sensitivity to ksp inhibitors
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
WO2003060158A3 (en) Apoe genotype as a prognostic marker for hepatitis
WO2004013348A3 (en) Method for determining endoglycosidase enzyme activity
MXPA03001506A (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases.
WO2007020632A3 (en) Methods and compositions for determining a level of biologically active serum paraoxonase
DE60229043D1 (en) REARRANGED PANELEPITHELIC CARCINOMAN GENES II
AU2003212405A1 (en) Method for determining the scale of an observation area
WO2003081238A3 (en) Cytocapacity test

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP